Source comparison
TB-500 Bioavailability: Delivery Method Comparison
The following table compares the bioavailability, absorption kinetics, and practical considerations of each TB-500 administration route based on published pharmacokinetic data and research-grade peptide protocols. Subcutaneous Injection 90–95% 2–4 hours 10–12
This comparison does not assign a generated winner or score.
- The following table compares the bioavailability, absorption kinetics, and practical considerations of each TB-500 administration route based on published pharmacokinetic data and research-grade peptide protocols.
- Subcutaneous Injection
- 90–95%
- 2–4 hours
- 10–12 hours
- Requires sterile technique; minimal discomfort; suitable for self-administration
- Gold standard for TB-500 delivery. Highest bioavailability with predictable absorption kinetics
- Intramuscular Injection
- 85–90%
- 4–6 hours
- 14–16 hours
- Slower absorption; deeper injection required; slightly more discomfort than subcutaneous
- Viable alternative when extended plasma levels are desired; marginally lower bioavailability offset by longer half-life
- Oral Administration
- <5%
- Not applicable
- Convenient but enzymatically degraded before absorption; no meaningful systemic delivery
- Functionally non-viable. Peptide structure incompatible with gastrointestinal transit
- Intravenous Bolus
- ~100%
- Immediate
- 6–8 hours
- Rapid clearance; requires medical administration; no first-pass metabolism
- Highest initial plasma concentration but shortest duration. Research use only
- Nasal Spray
- 15–25%
- 1–2 hours
- 8–10 hours
- Bypasses hepatic metabolism; variable absorption depending on mucosal contact
- Experimental route with inconsistent results. Not standard practice for TB-500 protocols